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ILDAbstract Aim of the work: To analyze the serum levels of IL-33 in RA patients and to investigate
its relation to the clinical characteristics, laboratory investigations, joint erosions, functional status
and disease activity. Its relation to the presence of interstitial lung disease (ILD) was well thought-
out.
Patients and methods: The study included 50 RA patients and 30 matched control. Thorough
clinical examination, investigations, disease activity score (DAS-28) and health assessment ques-
tionnaire (HAQ) were considered in the patients. Bone erosion was evaluated and interstitial lung
disease (ILD) was identiﬁed on high-resolution computed tomography. The serum level of IL-33
was measured by enzyme-linked immunosorbent assay.
Results: Serum levels of IL-33 are signiﬁcantly higher in RA patients (106.96 ± 52.6 pg/ml) than
in healthy controls (46.9 ± 23 pg/ml) (p< 0.001). A signiﬁcant correlation was found between
IL-33 and the DAS28 (r= 0.4, p= 0.001), level of rheumatoid factor (r= 0.45, p= 0.001) and
with the presence of ILD (r= 0.3, p= 0.04). There were no gender differences and the level did
not signiﬁcantly correlate with the age or disease duration. The medications received had no
obvious effect on the IL-33 level. The level did not correlate with the HAQ. There was a signiﬁcant
correlation between the CT bone erosion scores the patient’s age, disease duration, rheumatoid nod-
ules and DAS28. The erosion score also signiﬁcantly correlated with the serum IL-33 levels in RA
patients (r= 0.71, p= 0.001).
100 S.M Abdel-Wahab et al.Conclusion: These data support the hypothesis that IL-33 may be involved in RA pathogenesis
and it may partly contribute to the bone erosion and ILD in RA patients.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) is an autoimmune disease charac-
terized by chronic inﬂammatory response, including synovial
proliferation and excessive proinﬂammatory cytokine produc-
tion, leading to eventual cartilage and bone destruction [1].
Several mediators and factors were reported to play a role in
Egyptian RA patients including oxidative stress [2–4],
T-regulatory cells (Treg) and the imbalance of the Treg/TH17
cytokine axis [5] and cytokines [6,7] have also been implicated
in the pathogenic mechanisms of RA. Several proinﬂamma-
tory cytokines are considered critical in forming the inﬂamma-
tory process of RA [1]. There has been much evidence
conﬁrming the involvement of IL-33 in RA.
Interleukin-33 (IL-33) is a newly reported cytokine of IL-1
family, which has been demonstrated to induce cytokine
syntheses and mediate inﬂammatory responses through its
receptor ST2. It is widely expressed in many tissues such as
the liver, lung, central nervous system and multiple types of
cells including epithelial, endothelial, smooth muscle, macro-
phages and ﬁbroblasts [8]. Moreover, it is mainly localized in
the nucleus but under appropriate signal stimulation such as
inﬂammation, IL-33 is processed and passively released from
necrotic cells or actively secreted into the extracellular milieu
[9]. Through binding to its receptor ST2, it functions as a
proinﬂammatory cytokine that participates in the development
and progression of many diseases including collagen-induced
arthritis (CIA) [10], inﬂammatory bowel disease [11],
autoimmune hepatitis, anaphylactic shock [12] and ischemia
reperfusion injury [13,14].
It has been reported that administration of sST2 fusion
protein dramatically attenuated disease severity by reducing
cellular inﬁltration in the joints, synovial hyperplasia and joint
erosion due to inhibiting the release of proinﬂammatory
cytokines comprising IL-6, IL-12, tumor necrosis factor-
alpha (TNF-a) and interferon-gamma (IFN-c). As high
expression levels of IL-33 in human RA synovium have been
discovered, treatment with an ST2 blocking antibody at
disease attenuated the severity of CIA and reduced joint
destruction. This highly suggested a critical contribution of
locally produced IL-33 to the pathogenesis of joint inﬂamma-
tion and destruction [10].
Interstitial lung disease is a dreaded complication of RA.
The most common pattern on high resolution computerized
tomography (HRCT) and histopathology is usual interstitial
pneumonia (UIP), with nonspeciﬁc interstitial pneumonia seen
less frequently. Pulmonary function testing most commonly
shows reduced diffusion capacity for carbon monoxide and
HRCT reveals a combination of reticulation and ground glass
abnormalities [15]. Three dimensions computed tomography
(3D-CT) is a tomographic imaging method offering high
resolution, especially of cortical bone and three dimensionalvisualization of calciﬁed tissue, allowing clear deﬁnition of
the margins of erosion. The 3D-CT can provide a clear impres-
sion of lesion extent, pattern, shape and proximity to adjacent
structures [16].
The aim of the present work was to analyze the serum
levels of IL-33 in RA patients and to investigate its relation
to the clinical characteristics, laboratory investigations, joint
erosions, functional status and disease activity. Its relation to
the presence of ILD was well thought-out.2. Patients and methods
This study was carried out on 50 RA cases diagnosed accord-
ing to ACR criteria of rheumatoid arthritis [17] were selected
from those attending the outpatient Rheumatology clinic of
Zagazig University. The patients were 9 males and 41 females,
their age ranged from 34 to 69 years with a mean age of
51.1 ± 9.6 years and the duration of the disease ranged from
5 to 23 years with a mean of 11.4 ± 4.9 years. Twenty age
and sex matched healthy controls were included. Patients with
liver disease, history of anaphylactic shock or ischemia and
any other rheumatic disease were excluded. The study was
approved by the local ethics committee and consent from the
patients was taken before being enrolled in the study.
Full history was taken from the patients, clinical examina-
tion performed, disease activity score in 28 joints (DAS28)
calculated [18] and function status estimated using the health
assessment questionnaire [19]. Laboratory investigations were
performed including complete blood count (CBC), Erythro-
cyte sedimentation rate (ESR), C-reactive protein (CRP) and
Rheumatoid factor (RF). Interleukin-33 (IL-33) was assessed
by Enzyme-Linked Immunosorbent Assay (ELISA) in both
patients and control.
2.1. Quantitative measurement of IL-33
Human IL-33 PicoKine ELISA Kit was used. The assay
employs an antibody speciﬁc for human IL-33 coated on a
96-well plate. Standards and samples are pipetted into the
wells and IL-33 present in a sample is bound by the immobi-
lized antibody. The wells are washed and biotinylated anti-
human IL-33 antibody is added. After washing away unbound
biotinylated antibody, HRP-conjugated streptavidin is pipet-
ted to the wells. The wells are again washed, a TMB substrate
solution is added and color develops in proportion to the
amount of IL-33 bound. The Stop solution changes the color
from blue to yellow, and the intensity of the color is measured
at 450 nm. We calculated the mean absorbance for each set of
duplicate standards, controls and samples, and subtracted the
average zero standard optical density. The standard curve was
plotted on log–log graph paper or by using Sigma plot
Table 1 Demographic, clinical and laboratory characteristics of RA patients and control.
Variable Patients
n= 50
Control
n= 30
p
Age (years) 51.1 ± 9.6
(34–69)
51 ± 9.4(35–69) 0.95
Gender
Males 12 (24) 7 (23.3)
Females 38 (76) 23 (76.6)
Disease duration (years) 11.4 ± 4.9
Morning stiﬀness (min) 45 ± 25.5
(5–120)
DAS28 3.8 ± 1.9
HAQ (0–3) 1.5 ± 0.7
CRP (mg/dl) 8.2 ± 14.4 1.7 ± 0.3 0.04
ESR (mm/hr) 37 ± 22.5 2 ± 5 0.001
RF titre (IU/ml) >20 (35%) <15 (67%)
(<15 = negative) >60 (55%) 15–30 (33%) 0.01
<15 (10%)
IL-33 (pg/ml) 106.96 ± 52.6 46.9 ± 23 <0.001
(25–250) (15–110)
DAS28, disease activity score in 28 joints; HAQ, health assessment questionnaire; CRP, C-reactive protein; ESR,
erythrocyte sedimentation rate; RF, rheumatoid factor. Bold values are signiﬁcant at p< 0.05. Results are presented
as mean ± SD (range) or number (%).
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absorbance on the y-axis. The best-ﬁt straight line through
the standard points was drawn.
2.2. Computed tomography (CT)
All patients were examined in Radiodiagnosis department (CT
unit) in Zagazig University. Toshiba Activion multidetector
CT scanner (Toshiba Medical Systems) was used for all
examinations.
2.2.1. Three dimension computed tomography (3D-CT) of the
wrist
Scan parameters: 90 kV, 100 mA s, pitch 0.4 mm, slice spacing
0.4 mm, overlap 50%. Patients were placed in a prone position
with the arm stretched and the palm facing down. Images with
a voxel size of 0.4 mm · 0.4 mm · 1.0 mm were obtained.
Erosions on CT images were deﬁned as a sharply demarcated
area of focal bone loss seen in two planes, with a cortical break
(loss of cortex) seen in at least one plane. CT bone erosions
were scored according to Døhn et al. [25]. All wrist bones were
assigned a score by the percentage of bone volume involved
(score 0–10, by 10% volume increments), leading to a total
erosion score for one wrist ranging from 0 to 150. Erosion
volume is calculated by software according to the formula:
Volero = R(Areaero · ST), where Volero is the erosion volume,
Areaero the erosion area on one slice and ST is the slice thick-
ness [20].
2.2.2. Chest high resolution computed tomography
High resolution CT was performed with table speed of 10 mm/s
and scan duration of 30 s. Scans were obtained at 120 KVP and
250 mA/s. While patients lying in supine position, scan was
performed during full inspiration after the examined patient
was instructed to hold breathing.Statistical analysis: The data are coded and checked to
statistical package for social science (SPSS) version 10. The
distributions of all variables were examined. Means and stan-
dard deviations were calculated for all normally distributed
continuous variables. For categorical variables, counts and
percentages were calculated. Pearson correlation was used
between two variables. The differences of data were evaluated
by Student’s t-test.3. Results
The study included 50 RA patients and 30 controls. Demo-
graphic, clinical and laboratory characteristics of RA patients
and control are presented in Table 1. There was signiﬁcant
difference between patients and control regarding the
CRP, ESR and RF titre. There was highly signiﬁcant increase
in the IL-33 level in patients compared to the control
(p< 0.001).
Fig. 1 presents the bone erosion scores at the wrist region of
the hand by 3DCT in the RA patients. Figs. 2 and 3 show the
3DCT erosion of 2 patients. It showed that the most common
site of the erosions were the metacarpal bases especially 2nd
and 3rd. Most of the erosions were on the radial sides of meta-
carpal bones. Data are not shown in the controls. There were
minimal cortical changes on metacarpals in 9 patients (30%)
their ages were above 50 years. The radiological pattern for
ILD as detected by HRCT found honey combing (ﬁbrosis)
in 26 patients, multifocal peripheral consolidations in 14,
mixed pattern in 20 and a ground glass appearance (alveolitis)
in 40 patients.
Table 2 shows no signiﬁcant correlation between IL-33
levels and patients’ age or disease durations. There was a sig-
niﬁcant correlation between IL-33 level and both the DAS
28 (r= 0.4, p= 0.001) and RF titre (r= 0.45, p= 0.001).
There was no signiﬁcant correlation of the IL-33 levels with
Figure 1 Bone erosion score at the wrist by 3DCT in rheumatoid arthritis patients.
Figure 2 A three dimension computed tomography (3DCT)
(oblique view) hand and wrist of a 50 years old rheumatoid
arthritis patient with 13 years disease duration. Arrow shows
erosion at the MCP base (scored 4) with amalgamation of the
carpal bones.
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icant correlation between IL-33 and the presence of interstitial
ﬁbrosis (r= 0.3, p= 0.04).
Table 3 shows a signiﬁcant correlation of CT bone erosion
score with the age, disease duration, rheumatoid nodules and
DAS28. There was a signiﬁcant correlation between the CT
bone erosion scores and the serum IL-33 levels in RA patients
(r= 0.71, p= 0.001).4. Discussion
Interleukin-33 is the latest member of IL-1 family. It is broadly
expressed in many tissues but is restricted in cellular distribu-
tion to smooth muscles, epithelial cells, ﬁbroblasts, dendritic
cells and activated macrophage [21]. Recently, evidence has
shown that IL-33 contributes to the pathogenesis of RA due
to its increasing production of autoimmune inﬂammatory
mediators as proinﬂammatory cytokines and chemokines [22].
Our study showed increased serum IL-33 in RA patients
compared to control which is in agreement with the results
of the previous studies [23,24] indicating that it may be
involved in the pathogenesis of RA. In this study there were
no signiﬁcant correlation between IL-33 and disease duration
which disagrees with the results of Xiangyang and colleagues
[25].
There was a signiﬁcant correlation between IL-33 and RF
titre which did not match the results of Mu and colleagues
[24] and Xiangyang and colleagues [25]. In this study we
showed that there was no signiﬁcant correlation between
IL-33 levels and different type of treatment of RA. We used
3D-CT for a better visualization of the anatomic sites of the
joints prone to structural bone damage; we performed a 3-D
reconstruction of periarticular bone architecture to search
for further cortical bone changes linked to RA. In our study
we did not ﬁnd any signiﬁcant difference between radiographic
scores in males and females. This came in accordance with a
study done by Ahlmen and colleagues [26] who found a similar
degree of radiographic joint destruction in women compared
with men.
In our study erosion scores were strongly correlated with
disease duration and age. This erosion scores were also corre-
lated to disease activity in RA patients measured by the
DAS28. These results agree with the results of Stach and
colleagues [27] who found that erosion scores signiﬁcantly
correlated with DAS28 as a measure of activity in patients.
We found signiﬁcant correlation between radiographic RA
scores and RF titre and the presence of nodules. This agreed
with the prospective study done by Bukhari and colleagues
[28] as they reported that the RF titre, the presence of rheuma-
toid nodules, and number of swollen joints were signiﬁcantly
correlated to radiographic scores.
Figure 3 Three dimension computed tomography (3DCT) (posteroanterior view) hand and wrist of a 60 year old rheumatoid arthritis
patient with 15 years disease duration. Arrow shows erosion of the carpal bones (scored 4) with amalgamation of the carpal bones. Arrow
head shows erosion of the ulna (scored 7).
Table 2 Correlation of serum IL-33 level with various
parameters in the rheumatoid arthritis patients.
Serum IL-33 level in RA patients (n= 50)
Variables t or r p
Age (years) 0.2 0.11
Gender 0.54 0.59
Disease duration (years) 0.14 0.5
DAS 28 0.4 0.001
HAQ 0.22 0.11
Rheumatoid factor 0.45 0.001
Rheumatoid nodules 0.11 0.09
Morning stiﬀness 0.22 0.09
Interstitial ﬁbrosis 0.3 0.04
Medications
Methotrexate 1.05 0.29
Corticosteroids 1.04 0.3
Sulfasalazine 0.11 0.9
Antimalarial 0.05 0.95
Azathioprine 1.04 0.95
DAS28, disease activity score in 28 joints; HAQ, health assessment
questionnaire. Bold values are signiﬁcant at p< 0.05.
Table 3 Correlation between CT erosion scores with various
disease parameters and with IL-33 in rheumatoid arthritis
patients.
CT erosion score in RA patients (n= 50)
Variable r p
Age (years) 0.51 0.01
Gender 0.06 0.22
Disease duration (years) 0.45 0.01
DAS28 0.34 0.03
HAQ 0.11 0.09
Rheumatoid factor 0.4 0.05
Rheumatoid nodules 0.44 0.04
Morning stiﬀness 0.11 0.09
Serum IL-33 level 0.71 0.001
DAS28, disease activity score in 28 joints; HAQ, health assessment
questionnaire. Bold values are signiﬁcant at p< 0.05.
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IL-33 levels with DAS28 and the bone erosions score which
suggested a role of IL-33 with the disease activity and bone
erosions. Bone remodeling is modulated by the immune system
and the role of IL-33 in this context has been researched. Mun
and colleagues [29] studied the differentiation of osteoclasts
from human CD14+ monocytes, which is an osteoclast
progenitor. These cells express ST2 on their surfaces, indicat-
ing a possible role of IL-33 in this process. IL-33 caused theproduction of bone resorption factors (c-Src and cathepsin
K), showing the differentiation of viable osteoclasts. It is
important to note that receptor activator of nuclear factor-
kappaB ligand (RANKL) and IL-33 increase the expression
of ST2, suggesting positive feedback.
Interstitial lung disease is one of the serious complications
of RA. The pathogenesis of ILD in RA patients is unclear.
We compared the serum level of IL-33 between RA patients
with and without ILD. We found levels of IL-33 to be signif-
icantly higher in those with ILD; in this we match the results
of Xiangyang and colleagues [25]. Some studies showed that
ﬁbrogenesis is strongly linked with the development of T
helper type 2, CD4+ T cells. IL-33 plays a role in regulating
104 S.M Abdel-Wahab et al.Th2 cytokines and leads to increased IL-4, IL-5 and IL-13
expression in vivo. These show that IL-33 is associated with
TH2-driven pathology and in-particular those involved in pul-
monary ﬁbrosis [30].
In conclusion, this study supports the hypothesis that IL-33
may be involved in RA pathogenesis and it may partly con-
tribute to the bone erosion and ILD found in these patients.
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